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BACKGROUND: In the DAPA-HF trial (Dapagliflozin and Prevention of 
Adverse Outcomes in Heart Failure), dapagliflozin, added to guideline-
recommended therapies, reduced the risk of mortality and heart failure (HF) 
hospitalization. We examined the frequency and significance of episodes of 
outpatient HF worsening, requiring the augmentation of oral therapy, and 
the effects of dapagliflozin on these additional events.
METHODS: Patients in New York Heart Association functional class II to 
IV, with a left ventricular ejection fraction ≤40% and elevation of NT-
proBNP (N-terminal pro-B-type natriuretic peptide), were eligible. The 
primary outcome was the composite of an episode of worsening HF (HF 
hospitalization or an urgent HF visit requiring intravenous therapy) or 
cardiovascular death, whichever occurred first. An additional prespecified 
exploratory outcome was the primary outcome plus worsening HF 
symptoms/signs leading to the initiation of new, or the augmentation of 
existing, oral treatment.
RESULTS: Overall, 36% more patients experienced the expanded, in 
comparison with the primary, composite outcome. In the placebo group, 
684 of 2371 (28.8%) patients and, in the dapagliflozin group, 527 of 2373 
(22.2%) participants experienced the expanded outcome (hazard ratio, 0.73 
[95% CI, 0.65–0.82]; P<0.0001). Each component of the composite was 
reduced significantly by dapagliflozin. Over the median follow-up of 18.2 
months, the number of patients needed to treat with dapagliflozin to prevent 
1 experiencing an episode of fatal or nonfatal worsening was 16. Among 
the 4744 randomly assigned patients, the first episode of worsening was 
outpatient augmentation of treatment in 407 participants (8.6%), an urgent 
HF visit with intravenous therapy in 20 (0.4%), HF hospitalization in 489 
(10.3%), and cardiovascular death in 295 (6.2%). The adjusted risk of death 
from any cause (in comparison with no event) after an outpatient worsening 
was hazard ratio, 2.67 (95% CI, 2.03–3.52); after an urgent HF visit, the 
adjusted risk of death was hazard ratio, 3.00 (95% CI, 1.39–6.48); and after 
a HF hospitalization, the adjusted risk of death was hazard ratio, 6.21 (95% 
CI, 5.07–7.62).
CONCLUSION: In DAPA-HF, outpatient episodes of HF worsening were 
common, were of prognostic importance, and were reduced by dapagliflozin.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: 
NCT03036124.
© 2020 The Authors. Circulation is 
published on behalf of the American 
Heart Association, Inc., by Wolters 
Kluwer Health, Inc. This is an open 
access article under the terms of the 
Creative Commons Attribution License, 
which permits use, distribution, and 
reproduction in any medium, provided 
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The most commonly used outcome in clinical trials in patients with heart failure and reduced ejection fraction (HFrEF) is the composite of time to hospi-
talization for worsening heart failure or cardiovascular 
death, whichever occurs first.1–4 In recent years there 
has been a major effort to reduce the rate of hospital 
admission by treating worsening heart failure outside 
the traditional inpatient ward setting. This was recog-
nized in the updated Standardized Data Collection for 
Cardiovascular Trials Initiative cardiovascular and stroke 
end point definitions for clinical trials that included 
episodes of worsening heart failure if they resulted in 
intravenous treatment.5–7 However, such events are in-
frequent, even in contemporary trials.8–11 Many more 
patients are treated for worsening symptoms and signs 
in the community by means of the augmentation of 
oral therapy.11,12 The frequency and prognostic impor-
tance of such nonhospitalized episodes of worsening, 
treated with oral therapy, is not clear, in part, because 
these episodes have not been recorded in many trials 
and, where they have been recorded, such events have 
not been sought systematically or defined in a consis-
tent way. 8–12 In the placebo-controlled DAPA-HF trial 
(Dapagliflozin and Prevention of Adverse Outcomes in 
Heart Failure), dapagliflozin, added to other guideline-
recommended therapies, reduced the risk of mortality 
and heart failure hospitalization, and improved symp-
toms in 4744 patients with HFrEF.13–15 Episodes of 
outpatient worsening were collected systematically in 
DAPA-HF, and the analysis of these episodes was pre-
specified. We report the frequency of episodes of out-
patient worsening, the treatment given for them, the 
prognostic importance of these events, and the effect 
of dapagliflozin on them.
METHODS
DAPA-HF was a prospective, randomized, double-blind, con-
trolled trial in patients with HFrEF that evaluated the efficacy 
and safety of dapagliflozin 10 mg once daily, in comparison 
with matching placebo, added to standard care. The design, 
baseline characteristics, and primary results of the trial have 
been published.13–15 Ethics Committees at each of the 410 par-
ticipating institutions (in 20 countries) approved the protocol, 
and all patients gave written informed consent. Data underly-
ing the findings described in this article may be obtained in 
accordance with AstraZeneca’s data sharing policy.16
Study Patients
Men and women aged ≥18 years who had heart failure (HF) 
were eligible if they were in New York Heart Association 
(NYHA) functional class II to IV, had a left ventricular ejec-
tion fraction  ≤40%, and were optimally treated with phar-
macological and device therapy for HFrEF. Participants were 
also required to have an NT-proBNP (N-terminal pro-B-type 
natriuretic peptide) concentration ≥600 pg/mL (≥400 pg/mL 
if hospitalized for HF within the previous 12 months). Patients 
with atrial fibrillation or atrial flutter were required to have 
an NT-proBNP level ≥900 pg/mL, irrespective of history of HF 
hospitalization. Key exclusion criteria included symptoms of 
hypotension or systolic blood pressure <95 mm Hg, estimated 
glomerular filtration rate  <30 mL·min–1·1.73m–2 (or rapidly 
declining renal function), type 1 diabetes, and another condi-
tion likely to prevent patient participation in the trial or greatly 
limit life expectancy. A full list of exclusion criteria is provided 
in the design article.13
Study Procedures
After the provision of informed consent, visit 1 started a 
14-day screening period during which the trial inclusion and 
exclusion criteria were checked and baseline information was 
collected. Visit 2 was the randomization visit, and random-
ization was stratified based on diagnosis of type 2 diabetes 
(defined as an established diagnosis or a glycohemoglobin 
level of ≥6.5% [≥48 mmol/mol]) at screening. After random-
ization, follow-up visits took place at 14 and 60 days, and 
then at 120, 240, and 360 days, and every 4 months thereaf-
ter. The visit early after randomization (14 days) was included 
Clinical Perspective
What Is New?
• In this prespecified analysis of the DAPA-HF trial 
(Dapagliflozin and Prevention of Adverse Out-
comes in Heart Failure), we found that, in compari-
son with placebo, the sodium-glucose transporter 
2 inhibitor dapagliflozin reduced the risk of an epi-
sode of outpatient worsening of heart failure (HF) 
requiring intensification of oral HF therapy by 26%.
• Episodes of outpatient worsening of HF were com-
mon, affecting 1 in 8 patients during a median 
follow-up of 18 months and were prognostically 
important: after an outpatient intensification of HF 
therapy, patients had a ≈3-fold higher risk of death 
from any cause than patients experiencing no non-
fatal manifestations of HF during follow-up.
What Are the Clinical Implications?
• The frequency of episodes of outpatient HF wors-
ening requiring intensification of oral therapy, 
along with their prognostic importance and the 
availability of a therapeutic intervention to reduce 
them, should highlight their importance to clini-
cians and encourage preventative action.
• These findings may have potential consequences 
for the design of clinical trials: current outcome 
definition guidelines include only outpatient HF 
worsening events that are treated with intravenous 
therapy.
• Outpatient worsening events treated with oral 
therapy are more common than those treated with 
intravenous therapy and have similar prognostic 
significance; therefore, they should be consid-
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to check renal function and blood pressure (and for symptoms 
of hypotension, as well); this visit also allowed for adjustment 
of background diuretic or other nonessential therapies. Dose 
reduction to 5 mg of dapagliflozin or matching placebo (or 
discontinuation of study drug) was to be considered in case 
of an acute unexpected decline in the estimated glomerular 
filtration rate, volume depletion, or hypotension (or to avoid 
these conditions); however, dose uptitration (or reinitiation) 
was encouraged thereafter in all cases, where possible.
Study Outcomes
The primary outcome was the composite of an episode 
of worsening HF or cardiovascular (CV) death, whichever 
occurred first. An episode of worsening HF was defined as 
either an unplanned hospitalization or an urgent visit resulting 
in intravenous therapy for HF. Secondary outcomes included 
the composite of the occurrence of HF hospitalization or CV 
death. Additional prespecified exploratory end points included 
a wider composite reflecting worsening HF, namely time to first 
occurrence of CV death, hospitalization for HF, an urgent HF 
visit, or worsening HF symptoms/signs leading to the initiation 
of new oral therapy or augmentation of existing oral treat-
ment. Outpatient intensification of HF therapy was recorded 
by means of check box questions (yes/no) asked at each study 
visit and completed by the investigator on a specific case report 
form page: was there outpatient intensification of HF medica-
tion because of worsening symptoms/signs of HF, and, if so, 
was the dose of diuretic increased and sustained for at least 4 
weeks, or was a new drug added for the treatment of wors-
ening HF and sustained for at least 4 weeks? Further check-
box questions (yes/no) recorded any changes in the following 
medication classes: angiotensin-converting enzyme inhibitor, 
angiotensin receptor blocker, angiotensin receptor-neprilysin 
inhibitor, β-blocker, mineralocorticoid receptor antagonist, loop 
diuretic, other diuretics (eg, a thiazide), vasodilators, and other 
HF medications (eg, ivabradine, digitalis glycoside). We exam-
ined the effect of dapagliflozin, in comparison with placebo, 
on this expanded composite outcome and its components. 
Because reporting of episodes of outpatient worsening often 
occurred at the time of a study visit (or when another event 
occurred), it was not always certain whether such episodes 
occurred before or after a hospital admission, if both events 
occurred in a window between visits. Therefore, we performed 
a sensitivity analysis that included only episodes of outpatient 
worsening that were not preceded or followed by a HF hospi-
talization in the same time window between study visits.
We also examined the characteristics of patients experienc-
ing each manifestation of nonfatal worsening of HF and CV 
death, and the subsequent survival of patients having a nonfatal 
episode of worsening. In the latter analysis, patients with an 
urgent HF visit or hospitalized for HF within a 30-day period 
after outpatient intensification of HF therapy were classified as 
either an urgent HF visit or HF hospitalization, respectively. If 
patients were hospitalized within 30 days after an urgent HF 
visit, they were classified as a HF hospitalization and not an 
urgent HF visit. The reference group consisted of patients who 
had none of these events during the trial (no-event group). In a 
sensitivity analysis, the time period used to determine indepen-
dent events was shortened to a 7-day interval between events 
instead of 30 days. A further sensitivity analysis was performed 
limiting the definition of outpatient HF-worsening events to 
include only those in whom the dose of diuretics was increased 
and sustained for at least 4 weeks.
Statistical Analysis
Baseline characteristics were compared between groups by 
using the Kruskal-Wallis test or analysis of variance (ANOVA) 
for continuous variables and the χ2 test for categorical vari-
ables. The effect of dapagliflozin in comparison with placebo 
on each outcome was examined by means of hazard ratio 
(HR) and 95% CIs derived from Cox proportional hazards 
models, stratified according to diabetes status, and adjusted 
for a history of hospitalization for HF and treatment-group 
assignment. The effect of dapagliflozin in comparison with 
placebo on the total (including recurrent) number of outpa-
tient intensification of HF therapy events was examined by 
means of a semiparametric proportional rates model.17 The 
relative hazard of death after a first event was examined 
in a Cox proportional hazards model where an indicator of 
a patient’s first event type was entered in the model as a 
time-updated covariate (with follow-up time starting at ran-
domization). The model was repeated with stratification by 
diabetes status and adjusted for treatment-group assignment 
and a history of hospitalization for HF. Further adjustment was 
performed for the following variables at baseline: age, sex, 
region, race, NYHA functional classification, left ventricular 
ejection fraction, body mass index, pulse, systolic blood pres-
sure, serum creatinine, log NT-proBNP, history of atrial fibril-
lation, stroke, myocardial infarction, hypertension, ischemic 
cause, and the use of an implantable cardioverter defibrillator 
or  cardiac resynchronization therapy or both. All P values are 
2-sided and P<0.05 was considered significant. All analyses 
were performed using Stata version 16.0 (Stata Corp).
RESULTS
Of the 4744 patients randomly assigned in DAPA-HF, 
604 (12.7%) had outpatient worsening of HF resulting 
in intensification of therapy, 33 (0.7%) had an urgent 
HF visit resulting in intravenous therapy, 549 (11.6%) 
were hospitalized for worsening HF, and 500 (10.5%) 
died of CV causes at some point during follow-up.
First Episode of Worsening
The first nonfatal manifestation of HF was an outpa-
tient episode resulting in intensification of HF therapy in 
407 (8.6%) patients (without a subsequent urgent HF 
visit or hospitalization for HF within 30 days). An urgent 
HF visit resulting in intravenous therapy was the first 
manifestation in 20 (0.4%) patients (with no previous 
intensification of therapy or subsequent hospitalization 
for HF within 30 days). Hospitalization for HF, without 
a preceding outpatient episode of worsening or urgent 
HF visit, was the first manifestation in 489 (10.3%) pa-
tients. CV death was the first manifestation of worsen-
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The number of patients experiencing this expanded 
4-component composite outcome (n=1211 patients) 
was substantially larger (38% more patients) than the 
number who experienced the conventional composite 
outcome of HF hospitalization or CV death (n=877). CV 
death was the first event in 295 of the patients, con-
tributing to the expanded composite outcome (24% of 
first events). This was compared with 329 CV deaths as 
the first event among the 877 patients experiencing the 
narrower, 2-component, conventional composite out-
come (38% of first events were a CV death).
Baseline Characteristics
The Table shows the baseline characteristics of patients 
according to their first manifestation of HF worsening 
(and these characteristics for patients with no event). 
In comparison with patients with no worsening dur-
ing follow-up, patients experiencing any worsening 
were in a more advanced NYHA functional class, had 
a much higher NT-proBNP level, and a higher heart 
rate, but lower systolic blood pressure and left ven-
tricular ejection fraction. Patients with any form of 
worsening HF event reported a lower (worse) Kansas 
City Cardiomyopathy Questionnaire  Total Symptom 
Score at baseline in comparison with those who had 
no worsening event. Patients with worsening HF also 
had a higher prevalence of diabetes, atrial fibrillation, 
and chronic kidney disease, and were more often 
treated with a diuretic and digoxin than those with 
no worsening.
In general, these trends were consistent for patients 
with each different nonfatal manifestation of worsen-
ing, but not always as clear for patients dying of a CV 
cause. Conversely, among patients dying of a CV cause, 
an ischemic cause was more common than among 
other patients. When considering outpatient worsen-
ing HF events in comparison with those who had no 
worsening event during follow-up, differences in NYHA 
functional class, heart rate, and the number of patients 
taking diuretics and digoxin were less apparent than 
the other manifestations of worsening HF.
Treatments Given for Episodes of 
Outpatient Worsening
Of the 407 patients with outpatient worsening, 313 
(76.9%) had intensification of diuretic treatment and 
186 (45.7%) were started on additional HF therapy 
(these changes in treatment were not mutually exclu-
sive). The addition of a new loop diuretic occurred in 
34 of 407 (8.4%), and another diuretic in 18 (4.4%) 
patients not taking those medications at baseline. Ad-
ditional changes to HF therapy (either a change in exist-
ing medication or a new treatment started) included an 
angiotensin-converting enzyme inhibitor or angiotensin 
receptor blocker in 72 (17.7%) patients, sacubitril/val-
sartan in 29 (7.1%), a β-blocker in 47 (11.5%), a min-
eralocorticoid receptor in 58 (14.3%), a vasodilator in 
11 (2.7%), and another HF medication in 49 (12.0%). 
Data were unavailable for 18 of the 186 (9.7%) pa-
tients who had new HF therapy added.
Effect of Dapagliflozin in Comparison 
With Placebo on Manifestations of 
Worsening HF
In a prespecified expanded, 4-component, composite 
outcome of time to first HF hospitalization, urgent HF 
visit, outpatient worsening event, or CV death (to-
tal number of events=1211), there was a highly sig-
nificant benefit of dapagliflozin over placebo: hazard 
ratio (HR), 0.73 (95% CI, 0.65–0.82), P<0.0001 (Fig-
ure 1). If the expanded composite outcome had been 
used as the primary outcome and the trial terminated 
once 844 events had accrued, the benefit of dapa-
gliflozin would have been similar: HR, 0.71 (95% CI, 
0.62–0.81); P<0.0001. In a sensitivity analysis consid-
ering only outpatient intensification events occurring 
without an HF hospitalization occurring in the same 
time window between 2 study visits, the beneficial ef-
fect of dapagliflozin in comparison with placebo was 
not modified with a HR of 0.71 (95% CI, 0.60–0.85). 
Dapagliflozin was superior to placebo in reducing each 
nonfatal manifestation of HF: the risk of hospitalization 
was reduced by 30% (95% CI, 17%–41%); P<0.0001; 
an urgent HF visit was reduced by 57% (95% CI, 
10%–80%); P=0.021; and outpatient worsening was 
reduced by 26% (95% CI, 13%–37%; P=0.0003; Fig-
ure 2). When considering first and recurrent episodes 
of outpatient worsening, dapagliflozin reduced the risk 
of these events by 30% in comparison with placebo 
(rate ratio, 0.70 [95% CI, 0.59–0.84]; P=0.0001).
When patients with outpatient worsening were 
evaluated in more detail, the intensification of a di-
uretic for >4 weeks occurred significantly less fre-
quently in patients treated with dapagliflozin: 213 
(9.0%) on dapagliflozin in comparison with 283 
(11.9%) on placebo (HR, 0.72 [95% CI, 0.61–0.87]; 
P=0.0004). The addition of new HF therapy occurred 
in 130 (5.5%) patients in the dapagliflozin group and 
180 (7.6%) patients in the placebo group (HR, 0.70 
[95% CI, 0.56–0.88]; P=0.002).
Absolute Risk Reduction With 
Dapagliflozin in Comparison With 
Placebo Expressed as a Number Needed 
to Treat 
The number of patients needed to treat with dapa-
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Table. Baseline Characteristics of Patients With Different First Manifestations of HF Worsening, or None, or Experiencing Cardiovascular Death
Characteristics














Age, y 66.1±10.9 67.0±10.8 66.1±10.9 67.2±10.9 66.8±11.1
Female sex 857 (24.3) 107 (21.9) 1 (5.0) 90 (22.1) 54 (18.3)
Baseline body mass index* 28.2±5.8 28.7±6.6 30.6±7.9 27.8±5.9 27.8±5.9
Race, n (%)†
  White 2506 (70.9) 342 (69.9) 12 (60.0) 262 (64.4) 211 (71.5)
  Black 151 (4.3) 39 (8.0) 3 (15.0) 21 (5.2) 12 (4.1)
  Asian 826 (23.4) 102 (20.9) 5 (25.0) 113 (27.8) 70 (23.7)
  Other 50 (1.4) 6 (1.2) 0 (0.0) 11 (2.7) 2 (0.7)
Region, n (%)
  North America 507 (14.4) 88 (18.0) 4 (20.0) 51 (12.5) 27 (9.2)
  South America 593 (16.8) 72 (14.7) 3 (15.0) 90 (22.1) 59 (20.0)
  Europe 1618 (45.8) 230 (47.0) 8 (40.0) 157 (38.6) 141 (47.8)
  Asia/Pacific 815 (23.1) 99 (20.2) 5 (25.0) 109 (26.8) 68 (23.1)
New York Heart Association functional classification
  II 2484 (70.3) 261 (53.4) 9 (45.0) 287 (70.5) 162 (54.9)
  III 1025 (29.0) 217 (44.4) 11 (55.0) 117 (28.7) 128 (43.4)
  IV 24 (0.7) 11 (2.2) 0 (0.0) 3 (0.7) 5 (1.7)
Heart rate, beats/min 71.1±11.4 73.4±12.3 77.3±11.5 71.9±13.1 72.3±12.0
Systolic blood pressure, mm Hg 122.7±16.1 119.1±16.9 121.6±19.9 118.5±17.0 120.7±16.1
Left ventricular ejection fraction, % 31.5±6.6 29.4±7.2 28.9±9.5 30.3±7.1 30.1±7.1












Median Kansas City Cardiomyopathy Questionnaire 
Total Symptom Score (IQR)
79.2 (61.5–93.8) 70.8 (52.1–86.5) 64.6 (52.1–80.2) 75.0 (54.2–89.6) 70.3 (54.2–87.5)
Principal cause of HF, n (%)
  Ischemic 1996 (56.5) 259 (53.0) 11 (55.0) 210 (51.6) 198 (67.1)
  Nonischemic 1246 (35.3) 191 (39.1) 7 (35.0) 166 (40.8) 77 (26.1)
  Unknown 291 (8.2) 39 (8.0) 2 (10.0) 31 (7.6) 20 (6.8)
Medical history, n (%)
  Hospitalization for HF 1625 (46.0) 280 (57.3) 9 (45.0) 207 (50.9) 130 (44.1)
  Atrial fibrillation 1296 (36.7) 226 (46.2) 8 (40.0) 180 (44.2) 108 (36.6)
  Diabetes‡ 1399 (39.6) 259 (53.0) 10 (50.0) 178 (43.7) 137 (46.4)
Estimated glomerular filtration rate
  Mean, mL·min–1·1.73 m–2 67.0±19.3 60.8±18.9 62.0±18.6 62.9±19.3 63.1±20.2
  Rate of <60 mL·min–1·1.73 m–2 1332 (37.7) 250 (51.1) 10 (50.0) 196 (48.2) 138 (46.8)
Device therapy, n (%)
  Implantable cardioverter-defibrillator§ 892 (25.2) 175 (35.8) 6 (30.0) 113 (27.8) 56 (19.0)
  Cardiac resynchronization therapy¶ 257 (7.3) 48 (9.8) 1 (5.0) 34 (8.4) 14 (4.7)
HF medication, n (%)
  Diuretic 2916 (82.5) 453 (92.6) 18 (90.0) 355 (87.2) 266 (90.2)
  Angiotensin-converting enzyme  inhibitor 2029 (57.4) 247 (50.5) 10 (50.0) 195 (47.9) 180 (61.0)
  Angiotensin receptor blocker 968 (27.4) 130 (26.6) 4 (20.0) 130 (31.9) 74 (25.4)
  Sacubitril-valsartan 363 (10.3) 68 (13.9) 4 (20.0) 55 (13.5) 18 (6.1)
  β-Blocker 3412 (96.6) 468 (95.7) 18 (90.0) 384 (94.3) 276 (93.6)
  Mineralocorticoid receptor antagonist 2508 (71.0) 349 (71.4) 13 (65.0) 278 (68.3) 222 (75.3)
  Digitalis 626 (17.7) 116 (23.7) 2 (10.0) 77 (18.9) 66 (22.4)
The ± values are means±SD. Percentages may not total 100 because of rounding. HF indicates heart failure; and IQR, interquartile range. 
*The body-mass index is the weight in kilograms divided by the square of the height in meters.
†Race was reported by the investigators.
‡An additional 82 patients in the dapagliflozin group and 74 in the placebo group had previously undiagnosed diabetes, which was defined as a glycohemoglobin level of 
≥6.5% (≥48 mmol/mol), as measured in a central laboratory at both screening and randomization.
§This category includes either an implantable cardioverter-defibrillator or cardiac resynchronization therapy with a defibrillator.
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DAPA-HF to prevent 1 patient from experiencing an 
episode of fatal or nonfatal worsening was: 21 for the 
composite of CV death or HF hospitalization, 21 for the 
primary (3-component) composite, and 16 for the ex-
panded 4-component composite.
Risk of Death After a Nonfatal Episode of 
Worsening
Among the 407 patients in whom the first manifesta-
tion of worsening was an outpatient episode associ-
ated with the intensification of oral therapy, 323 of 407 
(79.4%) did not have any further nonfatal episodes of 
worsening (of any type) or die of a CV cause; this num-
ber was 309 of 407 (75.9%) when considering death 
from any cause. Among the 407 patients with an out-
patient episode of worsening, 48 (11.8%) subsequently 
died of a CV cause (65 [16.0%] died of any cause).
Among the 20 patients in whom the first event was 
an urgent HF visit, 6 of 20 (30%) did not have any 
further nonfatal episodes of worsening (of any type) or 
die of a CV cause; this number was also 6 of 20 (30%) 
when considering death from any cause. Among the 
20 patients in whom an urgent HF visit was the first 
nonfatal manifestation of worsening, 6 of 20 (30%) 
consequently died of a CV cause and 7 (35%) died 
of any cause. Of the 489 patients in whom the first 
event was a HF hospitalization, 204 (41.7%) did not 
have any further nonfatal episodes of worsening (of 
any type) or die of a CV cause; this number was 201 
of 489 (41.1%) for death from any cause. Among the 
489 patients in whom a HF hospitalization was the first 
manifestation of worsening HF, death from a CV cause 
or from any cause occurred in 151 (31%) and 163 
(33%) patients, respectively,
Figure 3 shows the rate of death from any cause in 
patients with a first nonfatal manifestation of worsen-
ing HF, and the unadjusted risk of death by type of 
worsening, in comparison with patients with no wors-
ening. The adjusted risk of death (in comparison with 
patients with no event) was ≈6-fold higher after a HF 
hospitalization (HR, 6.21 [95% CI, 5.07–7.62]) and 
≈3-fold higher after an urgent HF visit (HR, 3.00 [95% 
CI, 1.39–6.48]) or after an outpatient episode of wors-
ening (HR, 2.67 [95% CI, 2.03–3.52]; Table I in the 
Data Supplement). Similar results were found when 
the definition of outpatient episodes of worsening HF 
was limited to include only those in whom the dose 
Figure 1. Kaplan-Meier curves for the expanded composite outcome of time to first cardiovascular death, hospitalization for heart failure, urgent 
heart failure visit, or outpatient intensification of heart failure therapy, according to treatment group.
Hazard ratios (HR) and 95% CIs were estimated with the use of Cox regression models, stratified according to diabetes status, with a history of hospitalization for 
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of diuretic was increased and sustained for at least 4 
weeks (Table II in the Data Supplement). The use of a 
7-day interval between events to identify independent 
events rather than 30 days also did not alter the re-
sults (Table III in the Data Supplement).
DISCUSSION
In the present report, we provide new data, extending 
the evidence that dapagliflozin is beneficial in patients 
with HFrEF.15,18 Our findings confirm that worsening 
of HF, leading to the augmentation of oral therapy in 
the outpatient setting, is common and such events 
are of prognostic importance.8–12 These episodes of 
outpatient worsening were reduced substantially and 
significantly by dapagliflozin. This finding is important 
for patient management.
Although our patients had predominantly mild 
symptoms and were very well treated with conven-
tional therapy, 1 in 8 patients experienced worsening 
of their HF requiring augmentation of oral therapy 
over a median follow-up period of just 18.2 months. 
Although not as prognostically important as episodes 
of HF worsening leading to hospital admission, epi-
sodes of worsening leading to augmentation of oral 
therapy in the outpatient setting were still associated 
Figure 2. Effect of dapagliflozin versus placebo on manifestations of worsening heart failure.
Hazard ratios and 95% CIs were estimated with the use of Cox regression models, stratified according to diabetes status, with a history of hospitalization for heart 
failure and treatment-group assignment as explanatory variables. CV indicates cardiovascular; and HF, heart failure.
Figure 3. Rate and risk of all-cause mortality after a first nonfatal heart failure worsening event.
The risk of each death from any cause relative to patient not experiencing an event after a first nonfatal heart failure worsening event is calculated by using Cox 
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with a ≈3-fold higher risk of death over the remain-
der of the trial, in comparison with patients without 
worsening. Adding these events to create an expanded 
time-to-first composite outcome illustrates the con-
siderable residual rate of fatal or nonfatal worsening 
still experienced by patients with HFrEF despite excel-
lent contemporary therapy. Specifically, in the placebo 
group, the rate of CV death or HF hospitalization (the 
conventional primary outcome in HF trials) was 15.3 
per 100 person-years, but the event rate rose to 22.6 
per 100 person-years for the broadest composite out-
come (4-component composite), clearly reinforcing the 
continuing need for additional effective treatments in 
HFrEF.11,12 Thus, focusing only on HF hospitalization 
underestimates the frequency of clinical worsening in 
HFrEF, overall, and fails to recognize the other mani-
festations of worsening that have serious implications, 
as we have highlighted previously.11 These episodes of 
outpatient worsening may be all-the-more important 
given the current emphasis on attempting to minimize 
hospital admissions in patients with HF.5,6
The rate of outpatient HF worsening resulting in 
augmentation of oral therapy in DAPA-HF was higher 
than the rate observed in the PARADIGM-HF trial (Pro-
spective Comparison of ARNI with ACEI to Determine 
Impact on Global Mortality and Morbidity in Heart Fail-
ure), in keeping with the higher rates of HF hospital-
ization and CV death in DAPA-HF.11 The rate of orally 
treated episodes of worsening was much higher than 
outpatient worsening leading to intravenous treat-
ment, a finding consistent with PARADIGM-HF, other 
trials, and clinical experience.8–12
Therefore, the 2 most common nonfatal manifesta-
tions of worsening HF captured in this analysis clearly 
were outpatient episodes leading to the augmentation 
of oral therapy and hospital admission. Treatment with 
dapagliflozin decreased each of these. Dapagliflozin re-
duced the risk of outpatient worsening by 26% (HR, 
0.74 [95% CI, 0.63–0.87]); the magnitude of this rela-
tive risk reduction was consistent with that observed 
for HF hospitalization (HR, 0.70 [95% CI, 0.59–0.83]). 
This new finding reinforces the important incremental 
therapeutic benefit of dapagliflozin in HF.15,19 Both the 
relative and absolute risk reductions of the expanded 
composite outcome with dapagliflozin, added to con-
ventional therapy, were substantial. The number of 
patients needed to treat to prevent 1 episode of fatal 
or nonfatal worsening was only 16, over the median 
duration of 18.2 months. Although this small number 
reflects a large absolute benefit, that overall benefit 
consists of events of quite different clinical significance, 
ranging from death from CV causes to episodes of 
worsening symptoms/signs treated in the outpatient 
setting with oral therapy. If only more severe events 
(HF hospitalization or CV death) are included, the num-
ber of patients needed to treat rises to 21 and, for CV 
death alone, the number of patients needed to treat 
is 52. The prognostic importance of these episodes of 
outpatient worsening, coupled with the availability of 
therapeutic interventions that reduce them, and other 
adverse outcomes, argues for efforts to highlight the 
clinical significance of outpatient worsening to all prac-
titioners involved in care of these patients, including in-
ternists, primary care physicians, and nurses.11,12
The finding in both DAPA-HF and PARADIGM-HF 
that outpatient worsening is much more likely to be 
treated with oral than intravenous treatment argues for 
revision of the uniform definitions for CV and stroke 
outcomes developed by the Standardized Data Collec-
tion for Cardiovascular Trials Initiative and the US Food 
and Drug Administration.7 These require use of intrave-
nous therapy for confirmation of an episode of outpa-
tient worsening. The similar prognostic importance of 
outpatient worsening, irrespective of whether therapy 
is given intravenously, and the response of both types 
of worsening to efficacious therapy support a change 
in this guidance.
As with other similar studies, there are some limita-
tions. Most patients in DAPA-HF were in NYHA class II 
at the time of randomization and the duration of fol-
low-up was relatively short. The rate of events may dif-
fer according to HF severity and the proportions of each 
type of event may differ according to HF severity and 
duration of follow-up. These limitations could affect 
the generalizability of our results. We did not collect 
information on the specific symptoms and signs inves-
tigators used to identify worsening of HF in the outpa-
tient setting. Documentation of this information might 
be considered if outpatient episodes of worsening are 
incorporated into the primary outcome of a future trial, 
and such episodes might also be adjudicated by an end 
point committee. We also did not document visits to 
an emergency department that did not lead to hospital 
admission, although we know from PARADIGM-HF that 
these are infrequent, and some may have been iden-
tified as episodes of worsening leading to the use of 
intravenous therapy but not to hospitalization.11
In summary, in DAPA-HF, outpatient episodes of HF 
worsening were common, predictive of mortality, and 
reduced by dapagliflozin. A focus on HF hospitalization 
underestimates the frequency of HF worsening and ig-
nores other events of prognostic importance that are 
preventable.
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